Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of$ 0.57. This compares to loss of $0.69 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 19.30%. A quarter ago, it was expected that this company would post a loss of$ 0.60 per share when it actually produced a loss of $0.57, delivering a surprise of 5%. Over the last four quarters, the company has s ...